8 terminated, 5 recruiting, 5 withdrawn, 3 active not recruiting. 21 Phase 1, 15 Phase 2.
Follow Refractory B Acute Lymphoblastic Leukemia: new trials by email Literature Review of Refractory B Acute Lymphoblastic Leukemia trials Research Report on Refractory B Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-08-11 |
| Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma Biospecimen Collection, Pomalidomide - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Recruiting | University of Michigan Rogel Cancer Center | 12 | 2026-08-26 | 2026-10-15 |
| Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 26 | 2026-05-13 | 2026-10-16 |
| Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-01 | 2024-07-12 | |
| A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat Anti-CD123 ADC IMGN632, Bone Marrow Aspiration and Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Withdrawn | Children's Oncology Group | 2023-08-01 | 2023-09-01 | |
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate - Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Sumithira Vasu | 54 | 2022-06-30 | 2026-05-29 |
| Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Cyclophosphamide, Cytarabine, Dexamethasone - Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2022-02-17 | 2025-08-11 |
| Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia Inotuzumab Ozogamicin, Quality-of-Life Assessment, Vincristine Sulfate Liposome - Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2021-01-21 | 2022-01-28 | |
| Blinatumomab Bridging Therapy for BALL Blinatumomab - B-cell Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia | Phase 2 | Terminated | Michael Burke | 2 | 2021-01-01 | 2025-05-13 |
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Acetaminophen, Dexamethasone, Diphenhydramine - Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Completed | City of Hope Medical Center | 13 | 2020-11-18 | 2026-01-28 |
| Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia Dual target CAR-T cell therapy - Dual-target CAR-T Cells, B ALL | Phase 1 / Phase 2 | Unknown | Shenzhen University General Hospital | 20 | 2020-10-20 | 2021-01-26 |
| CD19-Specific T Cells Post AlloSCT Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells, Cyclophosphamide, Fludarabine - B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 4 | 2020-06-26 | 2021-06-02 |
| Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia Etoposide, Doxorubicin, Vincristine - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Completed | University of Washington | 24 | 2019-09-24 | 2023-07-06 |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - CD19 Positive, CD22 Positive | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-05-15 | 2023-08-21 | |
| Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2019-05-08 | 2026-10-19 |
| Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Dexamethasone - Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 53 | 2019-04-03 | 2026-05-13 |
| ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia ADCT-602 - Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 37 | 2018-08-24 | 2025-12-12 |
| Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia Biospecimen Collection, Computed Tomography, Lumbar Puncture - Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 40 | 2018-08-13 | 2026-10-06 |
| Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Palbociclib, Dexamethasone - Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 7 | 2018-05-09 | 2025-05-15 |
| Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia Blinatumomab, Cyclophosphamide, Cytarabine - Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2018-04-18 | 2022-11-04 |
Showing 20 of 26. Sign in to see all of them.
Burkitt Lymphoma (26) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (5) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Leukemia, Biphenotypic, Acute (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Disease Progression (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Hairy Cell (1)
DNA Virus Infections (26) · Epstein-Barr Virus Infections (26) · Hemic and Lymphatic Diseases (26) · Herpesviridae Infections (26) · Immune System Diseases (26) · Immunoproliferative Disorders (26) · Infections (26) · Lymphatic Diseases (26) · Lymphoma (26) · Lymphoproliferative Disorders (26) · Neoplasms (26) · Neoplasms by Histologic Type (26) · Tumor Virus Infections (26) · Virus Diseases (26) · Lymphoma, B-Cell (23)
Cyclophosphamide (13) · Vincristine (10) · Biopsy (8) · Specimen Handling (8) · Cytarabine (7) · Dexamethasone (7) · Methotrexate (7) · Calcium Dobesilate (6) · blinatumomab (6) · merphos (6) · Inotuzumab Ozogamicin (5) · Prednisone (5) · Rituximab (5) · Spinal Puncture (5) · auricularum (5)
M.D. Anderson Cancer Center (8) · City of Hope Medical Center (3) · Children's Oncology Group (2) · Fred Hutchinson Cancer Center (2) · National Cancer Institute (NCI) (2) · ECOG-ACRIN Cancer Research Group (1) · Michael Burke (1) · Roswell Park Cancer Institute (1) · Second Affiliated Hospital of Xi'an Jiaotong University (1) · Shenzhen University General Hospital (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Sumithira Vasu (1) · University of Michigan Rogel Cancer Center (1) · University of Washington (1)
United States (23) · Puerto Rico (3) · China (2)
Elias Jabbour (2) · Jordan Gauthier (2) · Nitin Jain (2) · Aili He, MD, PhD (1) · Amandeep Salhotra (1) · Elias Jabbour, MD (1) · Eunice S Wang (1) · Ibrahim Aldoss (1) · Ibrahim T Aldoss (1) · Ivana Gojo (1) · Jennifer E Agrusa, MD (1) · Jin S Im (1) · Li Yu, Dr (1) · Margaret Kasner, MD (1) · Matthew A Kutny (1)
PMID 35622074, PMID 41671463, PMID 28859185, PMID 29352703, PMID 34515338, PMID 35007127, PMID 37131217, PMID 37187201, PMID 38207208, PMID 38324336, PMID 38551807, PMID 38722664, PMID 39415930, PMID 39820359, PMID 41026957
P30CA033572 (3), P30CA016672 (2), U10CA180886 (2), R01CA276374 (1), U10CA180820 (1), U10CA180821 (1), UM1CA186691 (1)